Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(4 sites)

China

Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing Municipality

Henan Cancer Hospital, Zhengzhou, Henan

The First Hospital of China Medical University, Shenyang, Liaoning

Shanxi Cancer Hospital, Taiyuan, Shanxi